Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 3
2017 5
2018 2
2019 1
2020 4
2021 4
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. Uppaluri R, et al. Among authors: zolkind p. Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695. Epub 2020 Jul 14. Clin Cancer Res. 2020. PMID: 32665297 Free PMC article. Clinical Trial.
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders.
Zhou L, Zeng Z, Egloff AM, Zhang F, Guo F, Campbell KM, Du P, Fu J, Zolkind P, Ma X, Zhang Z, Zhang Y, Wang X, Gu S, Riley R, Nakahori Y, Keegan J, Haddad R, Schoenfeld JD, Griffith O, Manguso RT, Lederer JA, Liu XS, Uppaluri R. Zhou L, et al. Among authors: zolkind p. J Immunother Cancer. 2022 Jan;10(1):e004034. doi: 10.1136/jitc-2021-004034. J Immunother Cancer. 2022. PMID: 35058328 Free PMC article.
Checkpoint immunotherapy in head and neck cancers.
Zolkind P, Uppaluri R. Zolkind P, et al. Cancer Metastasis Rev. 2017 Sep;36(3):475-489. doi: 10.1007/s10555-017-9694-9. Cancer Metastasis Rev. 2017. PMID: 28836124 Free PMC article. Review.
Targeted Proteomic Quantitation of NRF2 Signaling and Predictive Biomarkers in HNSCC.
Wamsley NT, Wilkerson EM, Guan L, LaPak KM, Schrank TP, Holmes BJ, Sprung RW, Gilmore PE, Gerndt SP, Jackson RS, Paniello RC, Pipkorn P, Puram SV, Rich JT, Townsend RR, Zevallos JP, Zolkind P, Le QT, Goldfarb D, Major MB. Wamsley NT, et al. Among authors: zolkind p. Mol Cell Proteomics. 2023 Nov;22(11):100647. doi: 10.1016/j.mcpro.2023.100647. Epub 2023 Sep 15. Mol Cell Proteomics. 2023. PMID: 37716475 Free PMC article.
Negative-Pressure Aerosol Cover for COVID-19 Tracheostomy.
Bertroche JT, Pipkorn P, Zolkind P, Buchman CA, Zevallos JP. Bertroche JT, et al. Among authors: zolkind p. JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):672-674. doi: 10.1001/jamaoto.2020.1081. JAMA Otolaryngol Head Neck Surg. 2020. PMID: 32343299 Free PMC article.
Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
Mudianto T, Campbell KM, Webb J, Zolkind P, Skidmore ZL, Riley R, Barnell EK, Ozgenc I, Giri T, Dunn GP, Adkins DR, Griffith M, Egloff AM, Griffith OL, Uppaluri R. Mudianto T, et al. Among authors: zolkind p. Clin Cancer Res. 2021 Apr 15;27(8):2326-2339. doi: 10.1158/1078-0432.CCR-19-4179. Epub 2021 Feb 5. Clin Cancer Res. 2021. PMID: 33547198 Free PMC article. Clinical Trial.
23 results